Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NNMT | P40261 | 2/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 6/20 | 0.38 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.38 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.36 |
| ▸ | AKR1C3 | P42330 | 3/20 | 0.36 |
| ▸ | AKR1C2 | P52895 | 3/20 | 0.36 |
| ▸ | CDC42 | P60953 | 1/20 | 0.36 |
| ▸ | RAC1 | P63000 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.36 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.35 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | APP | P05067 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24094501 | 0.86 | NNMT (0.42) | NNMTPTGS2PTGS1SIRT6HCRTR1 | |
| SCHEMBL30318715 | 0.84 | MC4R (0.41) | NNMTPTGS2PTGS1AKR1C3AKR1C2 | |
| SCHEMBL30340511 | 0.84 | MC4R (0.41) | NNMTPTGS2PTGS1AKR1C3AKR1C2 | |
| SCHEMBL24854145 | 0.84 | MC4R (0.41) | NNMTPTGS2PTGS1AKR1C3AKR1C2 | |
| SCHEMBL24094529 | 0.84 | MC4R (0.41) | NNMTPTGS2PTGS1AKR1C3AKR1C2 | |
| SCHEMBL24094514 | 0.84 | MC4R (0.41) | NNMTPTGS2PTGS1AKR1C3AKR1C2 | |
| SCHEMBL29002109 | 0.83 | NNMT (0.47) | NNMTPTGS2PTGS1SIRT6AKR1C3 | |
| SCHEMBL24853336 | 0.81 | NNMT (0.40) | NNMTPTGS2PTGS1SIRT6AKR1C3 | |
| SCHEMBL24094566 | 0.81 | NNMT (0.40) | NNMTPTGS2PTGS1SIRT6AKR1C3 | |
| SCHEMBL24853335 | 0.81 | NNMT (0.40) | NNMTPTGS2PTGS1SIRT6AKR1C3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116113635-B | Spiro compounds as melanocortin 4 receptor antagonists and uses thereof | 辉瑞公司 | 2025-03-18 | — | — | CN | disclosed |
| US-20250084084-A1 | Crystalline form of (2R)-2-(5-fluoro-2-methoxypyridin-4-yl)-1-[(2S)-7-methyl-6-(pyrimidin-2-yl)-3,4-dihydro-1H-spiro[1,8-naphthyridine-2,3-pyrrolidin]-1-yl]propan-1-one | PFIZER INC. (US) | 2025-03-13 | — | — | US | disclosed |
| EP-4161927-B9 | SPIRO COMPOUNDS AS MELANOCORTIN 4 RECEPTOR ANTAGONISTS AND USES THEREOF | PFIZER (US) | 2024-11-06 | — | — | EP | disclosed |
| EP-4161927-B1 | SPIRO COMPOUNDS AS MELANOCORTIN 4 RECEPTOR ANTAGONISTS AND USES THEREOF | PFIZER (US) | 2024-08-07 | — | — | EP | disclosed |
| US-20230174532-A1 | METHODS FOR ANTAGONIZING A MELANOCORTIN 4 RECEPTOR | PFIZER INC. (US) | 2023-06-08 | — | — | US | disclosed |
| US-20230174532-A1 | METHODS FOR ANTAGONIZING A MELANOCORTIN 4 RECEPTOR | PFIZER INC. (US) | 2023-06-08 | — | — | US | disclosed |
| US-20230174532-A1 | METHODS FOR ANTAGONIZING A MELANOCORTIN 4 RECEPTOR | PFIZER INC. (US) | 2023-06-08 | — | — | US | disclosed |
| CN-116113635-A | Spiro compounds as melanocortin 4 receptor antagonists and uses thereof | 辉瑞公司 | 2023-05-12 | — | — | CN | disclosed |
| US-11643412-B2 | Melanocortin 4 receptor antagonists and uses thereof | PFIZER INC. (US) | 2023-05-09 | — | — | US | disclosed |
| US-11643412-B2 | Melanocortin 4 receptor antagonists and uses thereof | PFIZER INC. (US) | 2023-05-09 | — | — | US | disclosed |
| US-11643412-B2 | Melanocortin 4 receptor antagonists and uses thereof | PFIZER INC. (US) | 2023-05-09 | — | — | US | disclosed |
| EP-4161927-A1 | SPIRO COMPOUNDS AS MELANOCORTIN 4 RECEPTOR ANTAGONISTS AND USES THEREOF | Pfizer Inc. (US) | 2023-04-12 | — | — | EP | disclosed |
| US-20230019853-A1 | MELANOCORTIN 4 RECEPTOR ANTAGONISTS AND USES THEREOF | PFIZER INC. (US) | 2023-01-19 | — | — | US | disclosed |
| WO-2023275715-A1 | METABOLITES OF SELECTIVE ANDROGEN RECEPTOR MODULATORS | PFIZER INC. (US) | 2023-01-05 | — | — | WO | disclosed |
| WO-2023275715-A1 | METABOLITES OF SELECTIVE ANDROGEN RECEPTOR MODULATORS | PFIZER INC. (US) | 2023-01-05 | — | — | WO | disclosed |
| WO-2021250541-A1 | SPIRO COMPOUNDS AS MELANOCORTIN 4 RECEPTOR ANTAGONISTS AND USES THEREOF | PFIZER INC. (US) | 2021-12-16 | — | — | WO | disclosed |
| WO-2021250541-A1 | SPIRO COMPOUNDS AS MELANOCORTIN 4 RECEPTOR ANTAGONISTS AND USES THEREOF | PFIZER INC. (US) | 2021-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250084084-A1 | Crystalline form of (2R)-2-(5-fluoro-2-methoxypyridin-4-yl)-1-[(2S)-7-methyl-6-(pyrimidin-2-yl)-3,4-dihydro-1H-spiro[1,8-naphthyridine-2,3-pyrrolidin]-1-yl]propan-1-one | CSPP1, PRNP, RPLP2 | NNMT 3779/4885PTGS2 2749/4885PTGS1 3042/4885 |
| US-20230019853-A1 | MELANOCORTIN 4 RECEPTOR ANTAGONISTS AND USES THEREOF | MC4R, MC3R, MC5R | NNMT 3218/4885PTGS2 4073/4885PTGS1 3632/4885 |
| US-20230174532-A1 | METHODS FOR ANTAGONIZING A MELANOCORTIN 4 RECEPTOR | MC4R, MC2R, NPY4R | NNMT 1576/4885PTGS2 3225/4885PTGS1 2704/4885 |
| US-11643412-B2 | Melanocortin 4 receptor antagonists and uses thereof | MC4R, MC3R, MC5R | NNMT 3218/4885PTGS2 4073/4885PTGS1 3632/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.